Abstract
We recently identified three sub-populations of refractory acute myeloid leukemia (AML) patients with distinct intrinsic resistance mechanisms. Furthermore, we were able to risk-stratify the overall survival of the patients and identify patients who would likely benefit from alternative therapies.